Relevant bibliographies by topics / Kidney disease

Academic literature on the topic 'Kidney disease'

Author: Grafiati
Published: 4 June 2021
Last updated: 4 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Kidney disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Kidney disease"

1

Verma, Dr Amit Kumar. "Periodontal Disease with Diabetes or Diabetes Kidney Disease." International Journal of Trend in Scientific Research and Development Volume-3, Issue-1 (December 31, 2018): 1043–51. http://dx.doi.org/10.31142/ijtsrd19176.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

S, Memon. "Hyponatremia in Chronic Kidney Disease." Open Access Journal of Urology & Nephrology 7, no. 2 (April 4, 2022): 1–7. http://dx.doi.org/10.23880/oajun-16000202.

Full text
Abstract:
Introduction: There is adequate literature written on hyponatremia, but not much seen in context of Chronic Kidney Disease (CKD). Patients become prone for this electrolyte derangement when they are afflicted with organ failure especially CKD. This vulnerability becomes even worse in ageing due to impaired sensitivity to fluid intake and often burdened with multiple comorbid. For the adequate management of hyponatremia, knowledge of volume status, age of patients and associated comorbid, and duration of hyponatremia are very important. Patients and Methods: This observational study was conducted in adult CKD admitted patients. Demographic information, history, and examination finding were noted. Then each patient underwent investigation i.e., serum sodium, urea, creatinine, spot urine sodium, chloride, potassium, urine and serum osmolality, random blood sugar and echocardiography and noted in questionnaire. CKD staging was done with the help of Modified of diet and Renal disease (MDRD) equation. Diagnosis/ Impression of patient and need of hypertonic saline (3%saline) were all noted along with final outcome whether sodium improved/unimproved, discharge/expired were noted in pre-formed questionnaire. Results: Analysis was done on 171 CKD patients with female to male ratio: 1.19/1 and mean age 55.8 ± 15.16. Hypertension was most prevalent comorbid. Hypovolemia was the most common volume status seen along with moderate hyponatremia and hypertonicity were frequently observed features. 23 out of 171 patients were symptomatic, 44(25.7%) had low Left Ventricular function. Mortality was noted at 9.4%. Conclusion: Overall outcome of patient remained satisfactory despite of presence of CKD and significant number of patients were severe hyponatremic. Predominant management for hyponatremia remained conservative along with treatment for primary disease. Symptomatic hyponatremia and low LV function were found to be contributing to bad outcomes while severity of hyponatremia did not influence badly.
APA, Harvard, Vancouver, ISO, and other styles
3

Parmar, Dr Jigar A., Anant G. Joshi, and Dr Manish Chakrabarti. "Dyslipidemia and Chronic Kidney Disease." International Journal of Scientific Research 3, no. 5 (June 1, 2012): 396–97. http://dx.doi.org/10.15373/22778179/may2014/123.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mal, Pooran, Muhammad Nadeem Ahsan, Mehwish Bukhari, and Abdul Manan Junejo. "CHRONIC KIDNEY DISEASE." Professional Medical Journal 25, no. 09 (September 9, 2018): 1380–85. http://dx.doi.org/10.29309/tpmj/18.4360.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bollenbecker, Seth, Brian Czaya, Orlando M. Gutiérrez, and Stefanie Krick. "Lung-kidney interactions and their role in chronic kidney disease-associated pulmonary diseases." American Journal of Physiology-Lung Cellular and Molecular Physiology 322, no. 5 (May 1, 2022): L625—L640. http://dx.doi.org/10.1152/ajplung.00152.2021.

Full text
Abstract:
Chronic illnesses rarely present in a vacuum, devoid of other complications, and chronic kidney disease is hardly an exception. Comorbidities associated with chronic kidney disease lead to faster disease progression, expedited dialysis dependency, and a higher mortality rate. Although chronic kidney disease is most commonly accompanied by cardiovascular diseases and diabetes, there is clear cross talk between the lungs and kidneys pH balance, phosphate metabolism, and immune system regulation. Our present understanding of the exact underlying mechanisms that contribute to chronic kidney disease-related pulmonary disease is poor. This review summarizes the current research on kidney-pulmonary interorgan cross talk in the context of chronic kidney disease, highlighting various acute and chronic pulmonary diseases that lead to further complications in patient care. Treatment options for patients presenting with chronic kidney disease and lung disease are explored by assessing activated molecular pathways and the body’s compensatory response mechanisms following homeostatic imbalance. Understanding the link between the lungs and kidneys will potentially improve health outcomes for patients and guide healthcare professionals to better understand how and when to treat each of the pulmonary comorbidities that can present with chronic kidney disease.
APA, Harvard, Vancouver, ISO, and other styles
6

Fatima, Tanveer, Aurangzeb Afzal, and Sania Ashraf. "CHRONIC KIDNEY DISEASE." Professional Medical Journal 25, no. 06 (June 9, 2018): 887–91. http://dx.doi.org/10.29309/tpmj/18.4418.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Paul, Binu M., and Gregory B. Vanden Heuvel. "Kidney: polycystic kidney disease." Wiley Interdisciplinary Reviews: Developmental Biology 3, no. 6 (September 3, 2014): 465–87. http://dx.doi.org/10.1002/wdev.152.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nishi, Shinichi. "Chronic Kidney Disease and Cardiovascular Disease: Progression of Arterial Diseases in Chronic Kidney Disease." Nihon Naika Gakkai Zasshi 105, no. 5 (2016): 791–92. http://dx.doi.org/10.2169/naika.105.791.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Neyra, Javier A., and Lakhmir S. Chawla. "Acute Kidney Disease to Chronic Kidney Disease." Critical Care Clinics 37, no. 2 (April 2021): 453–74. http://dx.doi.org/10.1016/j.ccc.2020.11.013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Idan, Ahmed Fadhil. "Effect of Coronavirus among Kidney Disease Patients." Journal of Communicable Diseases 54, no. 02 (June 30, 2022): 28–32. http://dx.doi.org/10.24321/0019.5138.202267.

Full text
Abstract:
Background: COVID-19 is a novel coronavirus disease caused by the severe acute respiratory syndrome coronavirus 2. Chronic kidney disease (CKD) is associated with an increased risk of both inpatient and outpatient pneumonia. Objective: To describe the effect of COVID-19 virus on patients with kidney disease and renal transplants and analyse the outcomes of patients at the time of the study. Patients and Method: This is a descriptive study conducted in Baghdad Medical City, Al Shifa Center (single centre study). The study included 13 RTPCR-positive patients who were screened in the inpatient and outpatient departments. All patients received treatment according to the Iraq Ministry of Health protocol with dose adjusted as per the glomerular filtration rate (GFR). Result: The mean age of participants was 51.46 years with males more than females. Among the positive cases, 2 had acute kidney injury (15.4%), 3 had chronic kidney diseases (23.1%), 5 had end-stage renal disease (38.5%), and 3 had had renal transplants (23.1%). 6 patients out of 13 were diabetic, 11 were hypertensive, and 1 patient had heart failure. 7 (53.8%) patients were given conservative treatment, 4 were given isolated conventional haemodialysis, and only 2 patients were kept in an intensive care unit on continuous renal replacement therapy. 2 male patients died during the treatment. Conclusion: Chronic kidney disease is a risk factor for COVID-19 infection and more mortality and infection were found in male patients as compared to female patients in our study.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Kidney disease"

1

Herrera, Añazco Percy, Holguín Edward Mezones, and Adrian V. Hernández. "Global kidney disease." Elsevier B.V, 2014. http://hdl.handle.net/10757/322401.

Full text
Abstract:
We read with interest the Lancet Series on Global Kidney Disease. Valerie Luyckx and colleagues describe the economics and medical management of chronic kidney disease in sub-Saharan Africa.1 We note clear similarities with patients in Peru. Indeed, in Peru, the Ministry of Health (MINSA)—which covers 70% of the population—does not have a comprehensive programme for the management of patients with chronic kidney disease, including renal replacement therapies. However, the Social Security System (Essalud)—which covers 20% of the population—has a chronic kidney disease programme.
Revisión por pares
APA, Harvard, Vancouver, ISO, and other styles
2

Wei, Jin. "Acute Kidney Injury and Chronic Kidney Disease." Scholar Commons, 2017. http://scholarcommons.usf.edu/etd/6780.

Full text
Abstract:
Ischemia and reperfusion are natural steps during kidney transplantation, and IRI is considered one of the most important nonspecific factors affecting allograft dysfunction. Transplanted organs experience several episodes of ischemia, in which cold ischemia occurs during allograft storage in preservation solutions. Even though cold ischemia has been studied extensively, all of the studies have been carried out in vitro and ex vivo models. There is no in vivo model available to examine renal IRI induced solely by cold ischemia. In the present study, we developed an in vivo mouse model to study renal IRI induced exclusively by cold ischemia through clamping the renal pedicle for 1 to 5 hours. During the ischemic phase, blood was flushed from the kidney with cold saline through a small opening on the renal vein. The kidney was kept cold in a kidney cup with circulating cooled saline, while the body temperature was maintained at 37℃ during the experiment. The level of kidney injury was evaluated by plasma creatinine, KIM-1, NAGL, GFR, and histology. Plasma creatinine was significantly increased from 0.15±0.04 mg/dl in the sham group to 1.14±0.21 and 2.65±0.14 mg/dl in 4 and 5-hours ischemia groups at 24 hours after cold IRI. The plasma creatinine in mice with ischemic time <3 hours demonstrated no significant increase compared with sham mice. Changes in KIM-1, NAGL, GFR and histology were similar to plasma creatinine. 65 In summary, we developed and characterized a novel in vivo IRI-induced AKI mouse model exclusively produced by cold ischemia.
APA, Harvard, Vancouver, ISO, and other styles
3

Philips, L. G. "Disease management in chronic kidney disease /." abstract and full text PDF (free order & download UNR users only), 2005. http://0-wwwlib.umi.com.innopac.library.unr.edu/dissertations/fullcit/1430446.

Full text
Abstract:
Thesis (M.B.A.)--University of Nevada, Reno, 2005.
"May, 2005." Includes bibliographical references (leaves 92-97). Online version available on the World Wide Web. Library also has microfilm. Ann Arbor, Mich. : ProQuest Information and Learning Company, [2005]. 1 microfilm reel ; 35 mm.
APA, Harvard, Vancouver, ISO, and other styles
4

Papadopoulos, Theofilos. "MiRNAs in kidney disease." Thesis, Toulouse 3, 2016. http://www.theses.fr/2016TOU30194/document.

Full text
Abstract:
Les microARNs sont reconnus comme des régulateurs essentiels de l'expression des protéines. Des anomalies dans leur fonction sont associées au développement de nombreuses pathologies.tiel des microARNs en tant que biomarqueurs ou cibles thérapeutiques dans une grande variété de pathologies. Dans le cadre de cette thèse, nous avons étudié :1) L'association des microARNs urinaires avec l'évolution de la maladie rénale chronique (MRC) chez l'adulte. La prévalence de la MRC est actuellement estimée à 5-10% de la population et est en constante augmentation. La détection précoce et l'identification de patients ayant une MRC progressant rapidement vers l'insuffisance rénale sont la clé pour une meilleure prise en charge de ces patients. Actuellement les outils non-invasifs comme l'albuminurie ou l'estimation du débit de filtration glomérulaire manquent de précision. Dans notre travail, nous avons tenté d'identifier les modifications urinaires des microRNAs afin d'identifier de nouveaux biomarqueurs non-invasifs associés à la progression de la MRC. Nous avons analysé les modifications des microARNs urinaires par séquençage à haut débit dans des échantillons d'urine de 70 patients atteints de MRC et corrélé leurs profils d'expression à la progression de la maladie. Cela a amené à l'identification de 25 microARNs urinaires (pvalue ajustée <0.05) potentiellement associés à la progression de la MRC. Parmi ceux-là, quatre microARNs (hsa-miR-34c-5p, hsa-miR-410-3p, hsa-miR-301b-3p, and hsa-miR-145-5p) ont été sélectionnés pour être validés dans une cohorte indépendante de 52 patients atteints de MRC. L'augmentation de l'abondance urinaire de hsa-miR-145-5p a été confirmée comme étant associée à la progression de la MRC. Des analyses in vitro de l'effet de l'inhibition de hsa-miR-145-5p dans les cellules rénales ont mis en évidence que ce microARN semblait être impliqué dans le processus de nécrose. En conclusion, cette étude nous a permis d'identifier hsa-miR-145-5p comme Ainsi, de nombreuses études s'intéressent au potenmarqueur potentiel de la progression de la MRC. 2) La présence de microARNs urinaires associés à la néphropathie obstructive, une maladie fréquemment rencontrée chez les enfants qui peut conduire, dans les cas graves, à l'insuffisance rénale précoce. Dans cette étude, nous avons utilisé la biologie des systèmes et avons combiné des données microARN et ARNm de néphropathie obstructive humaine et animale pour obtenir des informations sur les mécanismes possibles impliqués dans cette maladie. En particulier, nous avons étudié simultanément le miRNome urinaire de nourrissons présentant une obstruction de la jonction pyélo-urétérale et le miRNome et le transcriptome tissulaire rénal chez la souris dans le modèle animal d'obstruction urétérale unilatéral (OUU) partiel et néonatal. Plusieurs centaines de microARNs et d'ARNms étant modifiés, la combinaison des microARNs des deux espèces avec les ARNms cibles associés a permis de sélectionner les 5 microARNs et 35 ARNms les plus fortement associés à la néphropathie obstructive. Une validation in vitro et in vivo a mis en avant que let-7a-5p et miR-29-3p ainsi que deux nouvelles cibles potentielles, l'E3 ubiquitin-protein ligase (DTX4) et neuron navigator 1 (NAV1) étaient dérégulées au cours de cette pathologie. Cette étude est la première à corréler le modèle animal d'OUU partiel et néonatal avec l'obstruction pyélo-urétérale chez l'Homme dans une analyse intégrée de biologie des systèmes. Nos résultats ont révélé let-7a et miR-29b en tant que molécules potentiellement impliquées dans le développement de la fibrose dans la néphropathie obstructive via le contrôle de DTX4 chez l'homme et la souris, ce qui n'aurait pas été identifiable autrement
MicroRNAs are now recognized as key players in the regulation of proteins and any abnormality in their function is a cause for pathway instability, leading to pathological conditions. Numerous reports from a variety of pathologies provide new data about microRNAs function, their targets and their potential as biomarkers and possible ways to control microRNAs' expression for potential therapeutic purpose. A number of reports also connect microRNAs with pathological conditions in the kidney and point to the use of microRNAs as biomarkers for diagnosis and prognosis of kidney disease in blood, serum, tissue and urine samples. In this thesis, we researched:1) A possible role of the microRNAs in the progression of adult chronic kidney disease (CKD), a disease representing a global burden with the tendency to rise worldwide. Progression of CKD is still very hard to detect non-invasively with the currently used clinical tools (eGFR and albuminuria). In our work we studied alterations of the level of the microRNAs in human urine samples of patients with fast or slow progression of CKD, in order to identify new potential biomarkers for non-invasive progression of CKD. Using Next Generation Sequencing, we analyzed urinary microRNA modifications in urine samples of 70 patients with established CKD and correlated their expression profiles to disease progression. This lead to the identification of 25 urinary microRNAs significantly associated to CKD progression (adjusted pvalue<0.05). Among those, four microRNAs (hsa-miR-34c-5p, hsa-miR-410-3p, hsa-miR-301b-3p, and hsa-miR-145-5p) were selected for validation in an independent cohort of 52 patients with CKD. Increased urinary abundance of hsa-miR-145-5p was confirmed to be associated to progression of CKD. In vitro exploration of the effects of hsa-miR-145-5p inhibition in human kidney cells showed that the microRNA seemed to be involved in necrotic processes. In conclusion we have identified hsa-miR-145-5p as potential urinary microRNA marker of CKD progression. 2) The identification of microRNAs associated to obstructive nephropathy, a frequently encountered disease in children that can lead, in severe cases, to end stage renal disease (ESRD). In this study we used a comprehensive system biology analysis in which we combined micro- and mRNA data from human and animal obstructive nephropathy to obtain information on possible mechanisms involved in this disease. In particular, we have studied in parallel the urinary miRNome of infants with ureteropelvic junction (UPJ) obstruction and the kidney tissue miRNome and transcriptome of the corresponding neonatal partial unilateral ureteral obstruction (UUO) mouse model. Several hundreds of microRNAs and mRNAs displayed changed abundance during disease. Combination of microRNAs in both species and associated mRNAs let to the prioritization of 5 microRNAs and 35 mRNAs associated to disease. In vitro and in vivo validation identified consistent dysregulation of let-7a-5p and miR-29-3p and new potential targets, E3 ubiquitin-protein ligase (DTX4) and neuron navigator 1 (NAV1). Our study is the first to correlate a mouse model of neonatal partial UUO with human UPJ obstruction in a comprehensive systems biology analysis. Our data revealed let-7a and miR-29b as molecules potentially involved in the development of fibrosis in UPJ obstruction via the control of DTX4 in both man and mice that would not be identified otherwise
APA, Harvard, Vancouver, ISO, and other styles
5

Ramzan, Naveen, Shimin Zheng, Hemang Panchal, Edward Leinaar, Christian Nwabueze, and Timir K. Paul. "Investigating The Association Between Chronic Kidney Disease and Clinical Outcomes." Digital Commons @ East Tennessee State University, 2019. https://dc.etsu.edu/asrf/2019/schedule/21.

Full text
Abstract:
Background Chronic Kidney Disease (CKD) can be described as the loss of the kidney function over time. Symptoms usually develop slowly, and it may not appear in early stages. Lab tests can confirm a CKD diagnosis. The approximate number of incidents per year is more than 200,000 cases, and approximately 30 million people are living with CKD today in the United States. This long-standing disease ultimately leads to renal failure at the end. At this present time, there are no known cures for CKD, and the only treatment available is dialysis. Objectives The purpose of this study is to determine the association between CKD and further with hemodialysis (HD) and medical condition such as cardiac complications, cardiogenic shock, hemorrhage, anemia, vascular complication, postop respiratory failure, post op infarct hemorrhage, acute renal failure, new temporary pacemaker, new permanent pacemaker, pericardial complications, and death. Study design The study employed secondary data in a cross-sectional design. Methods A sample of 106,969 was drawn from the population. The outcome variables were a diagnosis of CKD and/or CKD with HD. The predictor variables were cardiac complications, cardiogenic shock, hemorrhage, anemia, vascular complication, postop respiratory failure, post op infarct hemorrhage, acute renal failure, new temporary pacemaker, new permanent pacemaker, pericardial complications and death. Logistic regression was conducted to analyze the relationship between outcome variable and each independent variable. Variables with a p-value Results Analysis shows that subjects with cardiac complications were 17% less likely to have CKD as compared to those who did not have cardiac complications (OR: 0.83, 95% CI: 0.78-0.88). CKD patients who had cardiac complications were 18% more likely to have HD than the subjects who did not have cardiac complications (OR: 1.18, 95% CI: 1.01-1.39). Patients with cardiogenic shock were 86% more likely to have CKD than the subjects who did not have cardiogenic shock (OR: 1.86, 95% CI: 1.82-1.91). CKD patients who had cardiogenic shock were also 18% more likely to have HD than the subjects who did not have cardiogenic shock (OR: 1.18, 95% CI: 1.11-1.25). We have similar results if a patient had other conditions. Conclusion Chronic kidney disease with hemodialysis is significantly associated by the other medical conditions such as cardiac complications cardiogenic shock, hemorrhage, anemia, vascular complication, postop respiratory failure, post op infarct hemorrhage, acute renal failure, new temporary pacemaker, new permanent pacemaker, pericardial complications and death in the United States. Further studies are needed to confirm the results and to understand the prognosis.
APA, Harvard, Vancouver, ISO, and other styles
6

Gale, D. "Genetic investigation of kidney disease." Thesis, University College London (University of London), 2010. http://discovery.ucl.ac.uk/763753/.

Full text
Abstract:
Kidney disease is an important contributor to the burden of ill-health worldwide. Genetic factors have an important role in determining which people are affected by kidney disease, and this study aimed to identify the genes responsible for disease in families in which unusual kidney diseases were transmitted in a pattern suggesting autosomal dominant inheritance. I performed genome-wide single nucleotide polymorphism-based linkage studies and identified two new human disease genes. Hypoxia Inducible Factor-2α (HIF2α) is a widely expressed transcription factor which is rapidly broken down in the presence of oxygen. When oxygenation is reduced it activates the transcription of many genes, including erythropoietin which stimulates red blood cell production. I identified a heterozygous activating mutation of HIF2α which cosegregated with autosomal dominantly inherited erythrocytosis and pulmonary arterial hypertension in a British family, producing a phenotype similar to the effects of high altitude exposure. In vitro studies demonstrated that the mutant protein has increased transcriptional activity under normoxia. This suggests that HIF2α plays an important role in regulating the organism-wide responses to oxygen availability. Complement Factor H Related protein 5 (CFHR5) is a homologue of the complement regulating protein Complement Factor H and is of incompletely understood function. I uncovered an in-frame heterozygous duplication of exons 2 and 3 of the CFHR5 gene which cosegregated with autosomal dominantly inherited microscopic and synpharyngitic macroscopic haematuria, glomerulonephritis and renal failure in 2 families with ancestry in the Troodos Mountains of Cyprus. The mutation results in the production of a protein with impaired affinity for complement deposited in the kidney. This disease, which I named CFHR5 nephropathy, is endemic in Cyprus, accounting for a significant proportion of renal disease on the island, and may be amenable to systemic treatments. These findings implicate CFHR5 as a new and important regulator of complement in the human kidney.
APA, Harvard, Vancouver, ISO, and other styles
7

Wong, Germaine. "Cancer and chronic kidney disease." Thesis, The University of Sydney, 2008. https://hdl.handle.net/2123/28229.

Full text
Abstract:
Introduction Chronic kidney disease (CKD) is a common and important public health problem, with significant impact on the person’s quality of life and chances of survival. Cardiovascular disease is major cause of morbidity and mortality among people with CKD. Cancer is also a well-recognised complication in people on dialysis and with kidney transplants, but has not been adequately assessed in people with mild to moderately reduced kidney function. It is uncertain whether the basis of such increased risk in the end-stage kidney and transplant populations is solely related to their immunocompromised health states, or there are plausible biological reasons to explain the association beyond current knowledge. Screening, which allows early detection and subsequent treatment, is effective in reducing cancer-related deaths for common cancer such as breast, colorectal and cervical cancers in the general population. Given the inherent differences in the overall cancer risk and life expectancy among people with CKD, it is plausible that the effects, costs, and harms of routine population cancer screening may be different to the general population. This thesis is presented as published work on the theme of cancer and chronic kidney disease. The first chapter summarises the existing epidemiological evidence of association between cancer and kidney transplantation. The second chapter, uses data from the Blue Mountain Eyes Study cohort and linkage with the New South Wales Central Cancer Registry, explores the hypothesis of increased cancer risk in people with mild to moderately reduced kidney function. The work presented in the last five chapters of this thesis have extrapolated, critically appraised, and synthesized the available evidence for cancer screening in the general, end-stage kidney disease and kidney transplant populations.
APA, Harvard, Vancouver, ISO, and other styles
8

Brunmark, Charlott. "Type IV collagen and renal disease." Lund : Dept. of Nephrology, University of Lund, 1994. http://books.google.com/books?id=owdrAAAAMAAJ.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Antoniv, A. A. "Kidneys functional status in patients with chronic kidney disease and nonalcoholic steatohepatitis." Thesis, БДМУ, 2020. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/18082.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Patenaude, Anne-Marie. "Wnt signaling in kidney development and implication in polycystic kidney disease." Thesis, McGill University, 2005. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=84066.

Full text
Abstract:
Autosomal dominant polycystic kidney disease (PKD) is caused by mutations of the PKD1 or PKD2 genes. Cyst cells exhibit sustained expression of fetal genes such as PAX2. Normally, PAX2 is involved in kidney development and is rapidly downregulated after birth. Overactivity of the canonical beta-catenin signaling pathway has also been linked to the formation of renal cysts. To determine whether beta-catenin activity is linked to the level of PAX2 expression in vivo, we created a transgenic mouse overexpressing PAX2 in mature proximal tubules of the kidney. Here we report that the canonical beta-catenin signaling activity is increased in mice bearing the targeted PAX2 transgene.
There is also evidence that non-canonical Writ signaling may be involved in the development of renal cysts but this pathway is uncharacterized. We therefore studied the ontogeny of a downstream marker of this pathway (NFAT) and its localization in the developing kidney. Here we report that NFAT activity is high in early stages of kidney development and is rapidly downregulated at birth. The NFAT signal is diffuse and is expressed in both mesenchymal and epithelial cells of the developing kidney.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Kidney disease"

1

L, Watson Michael, and Torres Vicente E, eds. Polycystic kidney disease. Oxford: Oxford University Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

National Institutes of Health (U.S.), ed. Kidney disease. [Bethesda, Md.?]: National Institutes of Health, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

1959-, Goldsmith David, Jayawardene Satish, and Ackland Penny, eds. ABC of kidney disease. Malden, Mass: Blackwell Pub., 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

ABC of kidney disease. 2nd ed. Chichester, West Sussex: John Wiley & Sons, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Yang, Junwei, and Weichun He, eds. Chronic Kidney Disease. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-32-9131-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wada, Takashi, Kengo Furuichi, and Naoki Kashihara, eds. Diabetic Kidney Disease. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-9301-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Schulsinger, David A., ed. Kidney Stone Disease. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-12105-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Geary, Denis F., and Franz Schaefer, eds. Pediatric Kidney Disease. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-52972-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cowley,, Benjamin D., and John J. Bissler, eds. Polycystic Kidney Disease. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7784-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

1930-, Edelmann Chester M., and Meadow S. R, eds. Pediatric kidney disease. 2nd ed. Boston: Little, Brown, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Kidney disease"

1

Bowling, C. Barrett, and Rasheeda K. Hall. "Kidney Disease." In Geriatrics for Specialists, 305–16. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-31831-8_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Carpenter, William M., and Darren P. Cox. "Kidney Disease." In The ADA Practical Guide to Patients with Medical Conditions, 101–19. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781119121039.ch5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Axelsson, Thiane G., Michal Chmielewski, and Bengt Lindholm. "Kidney Disease." In Present Knowledge in Nutrition, 874–88. Oxford, UK: Wiley-Blackwell, 2012. http://dx.doi.org/10.1002/9781119946045.ch53.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bowling, C. Barrett, and Rasheeda K. Hall. "Kidney Disease." In Geriatrics for Specialists, 301–13. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-76271-1_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wolfe, Charles J. "Kidney Disease." In Over 55, 133–44. New York: Psychology Press, 2021. http://dx.doi.org/10.4324/9781315792651-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rosa, Margherita, and Salvatore Di Giulio. "Kidney Disease." In Crohn’s Disease, 249–57. Milano: Springer Milan, 2010. http://dx.doi.org/10.1007/978-88-470-1472-5_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gould, Edward R., and Anna Marie Burgner. "Glomerular Disease." In The Kidney, 175–97. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3286-3_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Joshi, Shreyas S., Gladell P. Paner, and Sam S. Chang. "Polycystic Kidney Disease." In The Kidney, 19–35. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3286-3_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Szczech, Lynda. "Disease State: Kidney Disease." In Management of Anemia, 1–10. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7360-6_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zhang, Rubin, and Anil Paramesh. "Transplantation: Kidney, Kidney–Pancreas Transplant." In Diabetes and Kidney Disease, 175–201. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0793-9_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Kidney disease"

1

Periyasamy, Kasi, and Venkateswaran Iyer. "Chronic Kidney Disease Helper." In 2020 IEEE International Conference on Healthcare Informatics (ICHI). IEEE, 2020. http://dx.doi.org/10.1109/ichi48887.2020.9374299.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

de Koning, Constance. "EMPA-KIDNEY: empagliflozin slashes kidney disease progression or CV death." In ASN Kidney Week 2022, edited by Rachel Giles. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/ce33490e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yildirim, Pinar. "Chronic Kidney Disease Prediction on Imbalanced Data by Multilayer Perceptron: Chronic Kidney Disease Prediction." In 2017 IEEE 41st Annual Computer Software and Applications Conference (COMPSAC). IEEE, 2017. http://dx.doi.org/10.1109/compsac.2017.84.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gao, Yaozong, Yiyi Ma, Guangrui Mu, Miaofei Han, Yiqiang Zhan, and Xiang Zhou. "Automatic MR kidney segmentation for autosomal dominant polycystic kidney disease." In Computer-Aided Diagnosis, edited by Horst K. Hahn and Kensaku Mori. SPIE, 2019. http://dx.doi.org/10.1117/12.2512372.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Fricks, Rafael B., Andrea Bobbio, and Kishor S. Trivedi. "Reliability models of chronic kidney disease." In 2016 Annual Reliability and Maintainability Symposium (RAMS). IEEE, 2016. http://dx.doi.org/10.1109/rams.2016.7448058.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kumari, Sandhya, and Bhagwate Dhiraj. "Kidney Disease detection through Iris Image." In 2018 3rd IEEE International Conference on Recent Trends in Electronics, Information & Communication Technology (RTEICT). IEEE, 2018. http://dx.doi.org/10.1109/rteict42901.2018.9012423.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pushpalatha, S., and A. Stella. "Kidney Disease Diagnosis using Classification Algorithm." In 2021 Fifth International Conference on I-SMAC (IoT in Social, Mobile, Analytics and Cloud) (I-SMAC). IEEE, 2021. http://dx.doi.org/10.1109/i-smac52330.2021.9640879.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Elsayed, Basant Moustafa, Lina Altarawneh, Suhail Doi, and Tawanda Chivese. "Association between pre-existing conditions and hospitalization, intensive care services and mortality from COVID-19 – a cross sectional analysis of an international global health data repository." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0151.

Full text
Abstract:
Objective: To investigate the association between pre-existing conditions and hospitalization, need for intensive care services (ICU) and mortality due to COVID-19. Methods: We used data on all cases recorded in the Global Health Data repository up to the 10th of March 2021 to carry out a cross-sectional analysis of associations between cardiovascular diseases (CVD), hypertension, diabetes, obesity, lung diseases and kidney disease and hospitalization, ICU and mortality due to COVID-19. We included data from Brazil, Mexico and Cuba only as they were the only countries where preexisting conditions were reported. We used multivariable logistic regression to compute adjusted and unadjusted odds ratios (OR) of the three outcomes for each pre-existing condition in ten-year age groups from 0-9 years and up to 110-120 years. Results: As of the 10th of March 2021, the Global Health repository held 25 900 000 records of confirmed cases of COVID-19, of which 2 900 000 cases from Brazil, Mexico and Cuba had data on preexisting conditions. The overall adjusted odds of hospitalization for each pre-existing condition were; CVD (OR 1.7, 95%CI 1.7-1.7), hypertension (OR 1.5, 95%CI 1.4-1.5), diabetes (OR 2.2, 95%CI 2.1-2.2), obesity (OR 1.7, 95%CI 1.6-1.7), kidney disease (OR 5.5, 95%CI 5.2-5.7) and lung disease (OR 1.9, 95%CI 1.8-1.9). The overall adjusted odds of ICU for each pre-existing condition were; CVD (OR 2.1, 95%CI 1.8-2.4), hypertension (OR 1.3, 95%CI 1.2-1.4), diabetes (OR 1.7, 95%CI 1.5-1.8), obesity (OR 2.2, 95%%CI 2.1-2.4), kidney disease (OR 1.4, 95%CI 1.2-1.7) and lung disease (OR 1.1, 95%CI 0.9-1.3). The overall adjusted odds of mortality for each pre-existing condition were; CVD (OR 1.7, 95%CI 1.6-1.7), hypertension (OR 1.3, 95%CI 1.3-1.4), diabetes (OR 2.0, 95%CI 1.9-2.0), obesity (OR 1.9, 95%CI 1.8-2.0), kidney disease (OR 2.7, 95%CI 2.6-2.9) and lung disease (OR 1.6, 95%CI 1.5-1.7). The odds of each outcome were considerably larger in children and young adults with these preexisting conditions than for adults, especially for kidney disease, CVD and diabetes. Conclusion: Individuals with CVD, hypertension, diabetes, obesity, lung diseases and kidney diseases have high odds of hospitalization, ICU and mortality from COVID-19. The odds of these outcomes are especially elevated in children and young adults with these preexisting conditions
APA, Harvard, Vancouver, ISO, and other styles
9

Huang, Zhongping, Jie Ren, and Anilchandra Attaluri. "Experimental Study of a Hybrid Renal Replacement System." In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14326.

Full text
Abstract:
Kidney failure is a major issue in the United States. The numbers of kidney failure patients are rapidly increasing with the simultaneous rise in diabetes, obesity and hypertension1. Kidney transplantation has shown excellent results, but insufficiency of donors has been a limiting factor. Most end-stage renal disease (ESRD) patients depend on hemodialysis (HD) for survival which is highly expensive. On an average ESRD patients receive 3 dialysis treatment a week and 4 hours per treatment, i.e., approximately 12 hours a week. Technology has not yet reached to a state where all the kidney functions can be mimicked. The only major kidney function being performed in HD is toxin removal. Even the toxins are not being continuously removed from the patients. To compensate the toxin and fluid removal of a whole week within 12 hours, high volumes of fluid are removed in HD treatments. Patients suffer due to the high fluid removal in a short period of time. Also the patients are restricted from taking fluids between the HD treatments. More frequent HD can improve both survival rate and life quality of patients with chronic kidney disease since normal people has his kidneys functioning continuously. It is a well known fact that daily dialysis offers many benefits over regular intermittent HD1. But providing daily dialysis is not affordable currently. Therefore, new modes of delivering continuous renal support are required.
APA, Harvard, Vancouver, ISO, and other styles
10

Snegha, J., V. Tharani, S. Dhivya Preetha, R. Charanya, and S. Bhavani. "Chronic Kidney Disease Prediction Using Data Mining." In 2020 International Conference on Emerging Trends in Information Technology and Engineering (ic-ETITE). IEEE, 2020. http://dx.doi.org/10.1109/ic-etite47903.2020.482.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Kidney disease"

1

Zhang, Mingzhu, Wujisiguleng Bao, Luying Sun, Zhi Yao, and Xiyao Li. Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: meta-analysis of randomized clinical trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0020.

Full text
Abstract:
Review question / Objective: To assess the beneficial effect and safety of finerenone for patients with chronic kidney disease associated with type 2 diabetes. Condition being studied: Chronic kidney disease (CKD) is a major contributor to morbidity and mortality from non-communicable diseases, affecting almost 700 million people worldwide. Approximately 40% of patients with diabetes have CKD, which exposes them to a 3-fold higher risk of cardiovascular death versus those with T2D alone. Strategies to protect the kidneys of patients with CKD and T2D may reduce their risk of cardiovascular events. Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced composite kidney and cardiovascular outcome in trials involving patients with chronic kidney disease. Recently, quite a few clinical studies have been conducted to compare finerenone and placebo. Our meta-analysis aimed to investigate the efficacy and safety of finerenone in chronic kidney disease associated with T2D. 1st author* - Mingzhu Zhang and Wujisiguleng Bao contributed equally to this study.
APA, Harvard, Vancouver, ISO, and other styles
2

Corey Goldman, Corey Goldman. What's Calcium's role in heart and kidney disease? Experiment, December 2013. http://dx.doi.org/10.18258/1719.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gusella, Gabriele L. Role of Integrin-Beta1 in Polycystic Kidney Disease. Fort Belvoir, VA: Defense Technical Information Center, April 2012. http://dx.doi.org/10.21236/ada562319.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dominguez, Jesus, K. J. Kelly, and Jizhong Zhang. Intravenous Renal Cell Transplantation for Polycystic Kidney Disease. Fort Belvoir, VA: Defense Technical Information Center, October 2013. http://dx.doi.org/10.21236/ada597871.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gusella, Gabriele L. Role of Integrin-Beta 1 in Polycystic Kidney Disease. Fort Belvoir, VA: Defense Technical Information Center, April 2011. http://dx.doi.org/10.21236/ada555405.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Murphy-Ullrich, Joanne E. The Endoplasmic Reticulum Stress Protein Calreticulin in Diabetic Chronic Kidney Disease. Fort Belvoir, VA: Defense Technical Information Center, July 2015. http://dx.doi.org/10.21236/ada624022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lin, Chun-Long. Prevalence and prognosis of pulmonary hypertension in patients with chronic kidney disease. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2023. http://dx.doi.org/10.37766/inplasy2023.2.0051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hua, Zi Bo, and Lv Yuan Chen. Human UCB MSC versus placebo for effect on kidney fibrosis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0104.

Full text
Abstract:
Review question / Objective: Human UCB MSC versus placebo for effect on kidney fibrosis Condition being studied: Renal fibrosis is the final outcome of long-term chronic kidney disease, and the kidney will lose its basic function. This experiment will explore the effect of Human UCB MSC for effect on kidney fibrosis. Main outcome(s): Correlation analysis of Human UCB MSC treatment on renalfibrosis.
APA, Harvard, Vancouver, ISO, and other styles
9

Hynes, Denise, Jose Arruda, Michael Berbaum, Ifeanyi Chukwudozie, Michael Fischer, Marian Fitzgibbon, Anna Porter, and Linda Schiffer. Evaluating a Patient-Centered Medical Home for Patients Receiving Dialysis for Kidney Disease. Patient-Centered Outcomes Research Institute® (PCORI), August 2019. http://dx.doi.org/10.25302/5.2019.ih.12115420.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kaatari, S., P. Turaga, and G. Wiens. Development of a vaccine for bacterial kidney disease in salmon. [und Renibacterium salmoninarum]. Test accounts, August 1989. http://dx.doi.org/10.2172/5301998.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Kidney disease' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography